HENLIUS (02696) announced on December 3, 2025, that the company has signed a cooperation agreement with Auven Pharma. Under the agreement, Auven Pharma grants the group exclusive commercialization rights for the licensed product in specified regions and fields.

This agreement follows a memorandum of cooperation signed on August 7, 2025 (a transaction exempt under the minimum threshold of the Listing Rules), under which the group obtained exclusive commercialization rights for the licensed product in China during the interim period until the formal agreement was executed. The memorandum stipulated that both parties would enter into a definitive agreement once certain conditions were met.

The memorandum has now been superseded by the cooperation agreement and automatically terminated on December 3, 2025. The licensed product, Fovistinib Citrate Capsules, a CDK4/6 inhibitor, has been approved for the treatment of HR+/HER2– breast cancer.

The introduction of this product aligns with HENLIUS’s commercialization strategy in breast cancer and complements its existing pipeline of breast cancer therapies, creating commercial synergies. The addition of the licensed product will further enrich the company’s portfolio and leverage its established breast cancer commercialization team and resources to enhance future revenue growth.